Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1

• Published in: Journal of translational medicine Vol. 21; no. 1; pp. 1 - 549
• Main Authors: Chen, Ruijiao, Hao, Xiaopeng, Chen, Jingyuan, Zhang, Changyue, Fan, Huixia, Lian, Fuming, Chen, Xiaochuan, Wang, Chao, Xia, Yong
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 16.08.2023; BioMed Central; BMC
• Subjects: Antibodies; Apoptosis; Biotechnology; Bladder cancer; Cancer therapies; Carcinoma; Care and treatment; Cell adhesion & migration; Cell culture; Cell cycle; Cell growth; Cell migration; Cell proliferation; Chemotherapy; Colorectal cancer; Computer simulation; Cytotoxicity; Diagnosis; DNA biosynthesis; Drug development; Drug dosages; Fatty-acid synthase; Flow cytometry; Immunofluorescence; Invasiveness; Jorunnamycin A; Lung cancer; Medical research; Muscle invasive bladder cancer; Phosphatidylserine; Proliferation; Proteins; Proteomics; Stem cells; Toxicity; Transcriptomics; Tumors; Urological surgery; Western blotting; China; Israel; United States > US; Japan
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04400-3

Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied. Methods To examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed. Results JorA inhibited the proliferation of MIBC cells, and the IC 50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in “cancer-related pathways” and “EGFR-related signaling pathways”, which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were − 8.153 and − 7.264 kcal/mol, respectively). Conclusions The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy. Graphical Abstract